Non-alcoholic fatty liver disease (NAFLD), now renamed as Metabolic Associated Steatotic Liver Disease (MASLD), has traditionally been seen as a condition affecting adults. However, alarming data now ...
Although metabolic dysfunction-associated steatotic liver disease (MASLD) has been proposed to replace the diagnosis of non-alcoholic fatty liver disease (NAFLD) with new diagnostic criteria since ...
Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that ...